Why bother with the HTA review if the system can already do almost anything it wants?

July 18, 2022 Latest News BioPharma Comment

This is a preview of subscriber content

Subscribe now to continue reading.

It seems that anything is possible under existing law and PBAC guidelines so patients still waiting for positive outcomes should certainly recalibrate their expectations. …

Subscribe now to continue reading.

Latest Video

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'
November 11, 2025 - Latest News
New Zealand accelerates medicines reform with major regulatory changes
November 12, 2025 - Latest News
Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'
November 11, 2025 - Latest News
'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'
November 11, 2025 - Latest News
HTA Review implementation group is recommending a defining role for AI
November 11, 2025 - Latest News

Why bother with the HTA review if the system can already do almost anything it wants?

This is a preview of subscriber content

Latest Video

Most Read

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

New Zealand accelerates medicines reform with major regulatory changes

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'

HTA Review implementation group is recommending a defining role for AI

New Stories

Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments

Sanofi building an AI-literate organisation through expectations, over experiments

Prospection says data access and leadership are critical to unlock AI’s potential in healthcare

The four 'H' words that can help drive the adoption of AI in health

Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity

PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal

New gene discoveries improve diagnosis of inherited heart disease

Sign In

Why bother with the HTA review if the system can already do almost anything it wants?

This is a preview of subscriber content

Latest Video

Most Read

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

New Zealand accelerates medicines reform with major regulatory changes

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'

HTA Review implementation group is recommending a defining role for AI

Follow Us

New Stories

Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments

Sanofi building an AI-literate organisation through expectations, over experiments

Prospection says data access and leadership are critical to unlock AI’s potential in healthcare

The four 'H' words that can help drive the adoption of AI in health

Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity

PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal

New gene discoveries improve diagnosis of inherited heart disease